400, boulevard Gonthier d’Andernach
Parc d’innovation CS80166 Cedex
Illkirch-Graffenstaden 67405
France
33 3 88 27 91 00
https://www.transgene.fr
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 141
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Alessandro Riva M.D. | CEO & Chairman of the Board | 72,27k | N/A | 1961 |
Ms. Lucie Larguier | Chief Financial Officer | N/A | N/A | N/A |
Dr. Eric Quemeneur Ph.D., Pharm.D. | Executive VP & Chief Scientific Officer | N/A | N/A | 1965 |
Mr. John Felitti J.D., LLM | VP, General Counsel & Corporate Secretary | N/A | N/A | 1970 |
Ms. Christelle Schwoerer | Chief Human Resources Officer | N/A | N/A | N/A |
Dr. Maud Brandely-Talbot M.D., Ph.D. | VP of Medical Affairs & Chief Medical Officer | N/A | N/A | 1954 |
Mr. James Wentworth M.B.A., Ph.D. | VP & Chief Business Officer | N/A | N/A | N/A |
Ms. Gaelle Stadtler | VP & Director of Human Resources | N/A | N/A | 1984 |
Kaidre Bendjama | Project Leader of Personalized Cancer Vaccines | N/A | N/A | N/A |
Ms. Elisabetta Castelli Ph.D. | Director of Investor Relations | N/A | N/A | N/A |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Transgene SAs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.